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The rs1803274 polymorphism of the BCHE
gene is associated with an increased risk of
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Abstract
Background: We sought to identify gene polymorphisms that confer susceptibility to in-stent restenosis after
coronary artery bare-metal stenting in a Central European population.
Methods: 160 controls without post–percutaneous coronary intervention in-stent restenosis were matched for age,
sex, vessel diameter, and diabetes to 160 consecutive cases involving in-stent restenosis of the target lesion within
12 months. Using real time polymerase chain reaction and melting-curve analysis, we detected 13 single-nucleotide
polymorphisms in 11 candidate genes - rs1803274 (BCHE gene), rs529038 (ROS1), rs1050450 (GPX1), rs1800849 (UCP3),
rs17216473 (ALOX5AP), rs7412, rs429358 (ApoE), rs2228570 (VDR), rs7041, rs4588 (GC), rs1799986 (LRP1) and rs2228671
(LDLR). Multivariable logistic regression was used to test for associations.
Results: The rs1803274 polymorphism of BCHE was significantly associated with in-stent restenosis (OR 1.934; 95 % CI:
1.181–3.166; p = 0.009). No association was found with the other studied SNPs.
Conclusions: The A allele of rs1803274 represents a risk factor for in-stent restenosis in Central European patients after
percutaneous coronary intervention with bare-metal stent implantation.
Background
Coronary stent implantation has significantly improved
percutaneous coronary intervention (PCI). It has enabled
management of early complications of plane balloon
angioplasty and prevention of elastic recoil and con-
strictive remodeling, decreasing the frequency of resten-
osis after PCI. However, with these improvements has
come a new complication: in-stent restenosis (ISR) aris-
ing from neointimal hyperplasia. The clinical incidence
of ISR after bare-metal stent (BMS) implantation is
about 20–35 % and currently represents one of the main
limitations of coronary angioplasty [1]. The use of
drug-eluting stents has led to a further decrease of ISR
occurrence to 5–10 % [1]. The known risk factors for
ISR include diabetes mellitus, renal insufficiency, lesion
length (20 mm), small vessel diameter (3 mm), treat-
ment of complex lesions (B2/C) [2], chronic total oc-
clusions, venous bypasses, ostial or bifurcation lesions,
stent undersizing or underexpansion and necessary im-
plantation of more stents [1]. The increasing number of
patients undergoing coronary interventions has led to
attempts to find further biochemical and genetic risk
factors that would enable more targeted treatment.
Based on a literature review, for the current study,
single nucleotide polymorphisms (SNPs) of some can-
didate genes were selected for having been associated
with ISR in different populations (Japanese and North
American) or in patients with repeated restenosis,
including BCHE - butyrylcholinesterase gene, ROS1 -
the closest homolog of the v-Ros oncogene of the
avian sarcoma, GPX1 - glutathione-peroxidase-1 gene,
UCP3 - uncoupling protein 3 gene, and ALOX5AP -
arachidonate 5-lipoxygenase-activating protein gene.
Our aim was to assess associations in our Central
European population [3–5]. Furthermore, we focused
on a group of genes affecting metabolic processes,
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including genes of apolipoprotein E (APOE), vitamin
D receptor (VDR), vitamin D binding protein (GC),
and two genes of the low density lipoprotein receptor
family, low density lipoprotein receptor related protein 1
(LRP1) and low density lipoprotein receptor (LDLR) which
may be involved not only in atherosclerosis but also in in-
flammation and may influence proliferation and migration
of vascular smooth muscle cells (VSMCs), key players in
the development of ISR [6–11].
Patient groups and methods
We included 160 consecutive patients treated at the
cathlab of the University Hospital Ostrava, Czech
Republic, between the years 2010 and 2013, with ISR
arising within 12 month after implantation of a bare-
metal stent. The control group was searched in the
Czech National PCI Registry and consisted of 160
matched patients treated at our cathlab with identical
main demographic and clinical risk factors (sex, age,
diabetes mellitus, implanted stent diameter ±0.5 mm) in
whom ISR was excluded using multi-slice (MS-CT)
coronarography scheduled at 12 months after the
implantation.
In order to determine frequency of the studied SNPs
in the general Czech population, genotyping was also
performed in 200 persons (100 Czech man-woman pairs
aged 26–66 years).
Selective coronarography
Selective coronarography was performed in a Siemens
Axiom device (Forchheim, Germany) using the standard
method from the right or left radial approach with 5 F
diagnostic catheters and the contrast medium Iomeron
400. Quantitative coronary angiography was performed,
and percent diameter stenosis (% DS) was calculated.
ISR was defined as a diameter stenosis ≥50 % in the
stented segment.
Multi-slice (MS) CT coronarography
All patients were examined without the need for previ-
ous premedication with beta-blockers in the Siemens
Somatom Definition AS+ device (Forchheim, Germany),
a single-source CT scanner in a 128-slice configuration.
The maximum intensity projection (MIP) reconstruc-
tions and automatic software Vessel analysis were used
for evaluation of the lumen. Homogeneous enhancement
(visually similar to the CT attenuation in the reference
vessels) inside the stent lumen was considered to be
normal or unrelated to ISR.
Genotyping of polymorphisms
The evaluated SNPs are listed in Table 1. The poly-
morphisms are described according to the HGVS no-
menclature [12], and their description corresponds
to the latest version available in the NCBI and
Ensembl gene databases.
Genomic DNA was extracted using the MagNA Pure
Compact Instrument (Roche, Switzerland). The real-
time PCR assays for genotyping of rs1803274 (BCHE),
rs529038 (ROS1), rs1050450 (GPX1), and rs1800849
(UCP3) were performed on the Rotor-Gene 3000A
instrument (Corbett Research/Qiagen, Netherlands) with
dual-labeled hydrolysis TaqMan® probes (Eastport, Czech
Republic; TIB MolBiol, Germany) and followed by allelic
discrimination and/or scatter analysis.
Primers and hybridization probes (TIB MOLBIOL,
Germany) were designed to detect rs17216473 (ALOX5AP),
rs2228570 (VDR), rs7041, rs4588 (GC), rs2228671 (LDLR),
and rs1799986 (LRP1) genotypes using melting curve ana-
lysis on the LightCycler 480 II system (Roche, Switzerland).
Primer and probe sequences are available on request.
Using these two methods, sample genotype was deter-
mined comparing the curves to positive samples whose
genotype was verified by Sanger sequencing using the ABI
Big Dye Terminator Cycle Sequencing Detection Kit v.3.1
(Applied Biosystems, USA) and genetic analyzer ABI3130
(Applied Biosystems, USA). Sanger sequencing was also
used to determine the genotype of samples with inconclu-
sive result of real-time PCR assay or melting curve analysis.
The ApoE*2, *3, and *4 (rs7412 and rs429358) geno-
types were determined using LightMix Kit ApoE C112R
C158R (TIB MOLBIOL, Germany).
Ethical statements
The study protocol complied with the Declaration of
Helsinki and was approved by the Ethics Committee of
the University Hospital Ostrava, Czech Republic. Written
informed consent was obtained from each participant.
Table 1 Selected single nucleotide polymorphisms
Polymorphism
Gene Coding DNA level Protein level NCBI database
BCHE c.1699G>A p.Ala567Thr rs1803274
ROS1 c.6637G>A p.Asp2213Asn rs529038
UCP3 c.-238C>T rs1800849
GPX1 c.599C>T p.Pro200Leu rs1050450
ALOX5AP c.117–5723G>A rs17216473
APOE*2 c.526C>T p.Arg176Cys rs7412
APOE*4 c.388 T>C p.Cys130Arg rs429358
GC c.1296 T>G p.Asp432Glu rs7041
GC c.1307C>A p.Thr436Lys rs4588
VDR c.2 T>C p.Met1Thr rs2228570
LRP1 c.300C>T p.Asp100= rs1799986
LDLR c.81C>T p.Cys27= rs2228671
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Statistical analysis
Statistical analysis was performed using SPSS version 15
(SPSS Inc., Chicago, IL, USA). Continuous clinical vari-
ables of the groups with non-normal distribution are
presented as the median and range (minimum–max-
imum) or lower and higher quartiles/Med (LQ–HQ)/
and were compared using the non-parametric Mann–
Whitney U test. Categorical clinical variables are pre-
sented as counts and percentages and were compared by
the chi-square test. The genotype distribution of each
SNP difference between the study and control groups
was analyzed by the chi-square test (or the Fisher’s exact
test in the case of lower frequencies). A p value of less
than 0.05 was considered significant. Consistency of the
observed genotype frequencies with the Hardy–Weinberg
distribution was determined by the chi-square test.
Multiple logistic regression was used to evaluate
possible effects of other variables on the association
observed between the individual SNPs and ISR.
Results
Basic demographic, clinical, and biochemical characteris-
tics of the cohort are listed in Table 2. The group of
patients with ISR and the control group did not differ
significantly in the main demographic parameters (age,
gender, body mass index) or clinical risk factors (diabetes
mellitus). The groups had a similar extent of coronary
disease (multi-vessel disease [2VD/3VD], acute coron-
ary syndromes [NSTEMI/STEMI]) and similar lesion
characteristics (complex lesion B2/C, length and diameter
[±0.5] mm of implanted stents). Furthermore, the group
had similar main biochemical parameters (creatinine,
TAG, hsCRP). However, total and LDL cholesterol was
significantly higher in the control group.
In the ISR group, the genotype was determined for all
the studied SNPs in 149 patients. Due to lack of DNA,
in five patients the genotype was obtained only for
rs1803274, rs529038, rs1050450, rs7412, rs429358 and
rs7041, in three patients only for rs1803274, rs529038,
and rs1050450 and in two patients for rs1803274 and
rs529038. In the non ISR group, the genotype was estab-
lished in all patients for all SNPs with the exception of
rs1803274 in 2 patients. Three per cent of the analysis
had to be repeated and one per cent to be sequenced.
All SNPs were in Hardy–Weinberg equilibrium. The
genotype distributions of the studied polymorphisms
and minor allele frequencies (MAF) among subjects with
ISR and those without restenosis and MAF data for
general Czech population are shown in Table 3. With
respect to a small number of minor allele homozygotes
of various SNPs, a statistical comparison of homozygotes
for the wild-type allele and carriers of the minor allele
(heterozygotes and homozygotes) was performed.
Evaluation of genotype distributions by the chi-square
test (or the Fisher’s exact test in the case of lower
frequencies) revealed that only the rs1803274 poly-
morphism of BCHE (c.1699G>A, p.Ala567Thr) was
associated with an increased risk of ISR (Table 3). The
ISR group had a significantly higher occurrence of het-
erozygous/homozygous carriers of the A allele (GA +
AA) (p = 0.009) compared to the control group.
Minor allele frequencies (MAF) were calculated in the
ISR and the non ISR groups and also in general Czech
population. We confirmed a significant difference in
rs1803274 MAF between the ISR and non ISR groups
(p = 0,007). There were no significant differences of
MAFs for the other SNPs. No difference was also found
between nor ISR neither non ISR group versus general
Czech population in any SNP (Table 3).
Multivariate logistic regression analysis with adjustment
for the prevalence of diabetes mellitus (the main BMS-ISR
clinical risk factor) confirmed that the rs1803274 poly-
morphism of BCHE was significantly associated with the
prevalence of ISR (Table 3). The A allele carriers (both het-
erozygous GA and homozygous AA) were at a 1.934 fold
(95 % confidence interval [CI]: 1.181–3.166; p = 0.009) in-
creased risk of ISR. Thus, the 1699A allele of the BCHE
polymorphism represented a risk factor for this condition.
No association was found between the other SNPs and ISR.
Discussion
Vascular injury sustained during PCI and bare-metal
stent implantation results in a complex inflammatory
Table 2 Clinical characteristics of all patients (including
matched controls) and angiographic parameters of coronary
artery lesions
In-stent restenosis Controls p
Age (years) 67.0 (59.0–74.0) 67.0 (62.0–71.0) 0.984
Male/Female 101/59 101/59 1.000b
Diabetes mellitus (%) 28.75 28.75 1.000b
BMI (kg/m2) 28.4 (25.7–31.2) 29.1 (25.9–32.0) 0.368
Creat (umol/L) 97 (86–115) 99 (87–116) 0.517
Chol (mmol/L) 4.27 (3.73–4.94) 4.50 (3.95–5.55) 0.046
TG (mmol/L) 1.62 (1.12–2.18) 1.58 (1.17–2.21) 0.644
LDL (mmol/L) 2.66 (2.27–3.19) 2.96 (2.45–3.67) 0.003
HDL (mmol/L) 1.25 (1.02–1.51) 1.21 (1.00–1.42) 0.354
hs-CRP (mg/L) 1.71 (0.82–3.76) 1.70 (0.85–3.88) 0.978
ACSy (stemi/nstemi) (%) 62.78 72.50 0.056b
Multi vessel dissease (%) 57.5 49.38 0.145b
B2/C lesions (%) 68.11 68.48 0.940b
Stent diameter (mm) 3.0 (2.0–4.5)a 3.0 (2.0–4.0)a 0.214
Stent lenght (mm) 19 (8–68)a 19 (8–86)a 0.680
Data are given as median (lower and higher quartiles) or amedian
(minimim–maximum). Quantitative parameters are given in percents
p, significance of Mann–Whitney U test or bchi-square test
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Table 3 Distribution of polymorphism genotypes in groups with and without ISR, minor alele frequencies (MAF) and logistic regression analysis, separately for each parameter
with adjustment for diabetes mellitus
Gene, polymorphism Distribution of polymorphism genotypes MAF in general CZ population, ISR
and non-ISR groups; statistics
Logistic regression analysis, compared to the wild type
allele with adjustment for diabetes mellitus
ISR group Non-ISR group p Czech
GP
ISR vs. GP Non-ISR vs GP OR 95 % CI for OR p
No of pts (%) No of pts (%) p p
BCHE, rs1803274 0.016
No of pts (n) 160 158
GG 102 (63.8 %) 122 (77.2 %)
GA 50 (31.2 %) 35 (22.2 %) 1.715 1.034 - 2.846 0.037
AA 8 (5 %) 1 (0.6 %) 0.008a 9.703a 1.191 - 79.05a 0.034a
GA + AA 58 (36.2 %) 36 (22.8 %) 0.009 1.934 1.181 -3.166 0.009
MAF 0.21 0.12 0.007 0.18 0.280 0.367
ROS1, rs529038 0.280
No of pts (n) 160 160
GG 75 (46.9 %) 78 (48.8 %)
GA 75 (46.9 %) 65 (40.6 %) 1.200 0.758 - 1.899 0.436
AA 10 (6.2 %) 17 (10.6 %) 0.269 0.612 0.263 - 1.421 0.253
GA + AA 86 (53.8 %) 82 (51.2 %) 0.823 1.078 0.695 - 1.672 0.737
MAF 0.3 0.31 1 0.3 1 1
UPC3, rs1800849 0.982
No of pts (n) 149 160
CC 86 (57.8 %) 90 (56.2 %)
CT 51 (34.2 %) 63 (39.4 %) 0.847 0.527 - 1.361 0.492
TT 12 (8.1 %) 7 (4.8 %) 0.323 1.792 0.670 - 4.793 0.245
CT + TT 63 (42.3 %) 70 (43.8 %) 0.795 0.939 0.597–1.477 0.785
MAF 0,25 0,24 1 0,28 1 0,696
GPX1, rs1050450 0.981
No of pts (n) 157 160
CC 72 (46 %) 76 (47.5 %)
CT 74 (47.1 %) 71 (44.5 %) 1.085 0.687 - 1.715 0.726
TT 10 (6.4 %) 13 (8.1 %) 0.788 0.801 0.331 - 1.941 0.623
CT + TT 84 (53.5 %) 84 (52.5 %) 0.811 1.041 0.670 - 1.619 0.857













Table 3 Distribution of polymorphism genotypes in groups with and without ISR, minor alele frequencies (MAF) and logistic regression analysis, separately for each parameter
with adjustment for diabetes mellitus (Continued)
ALOX5AP, rs17216473 1.000
No of pts (n) 149 160
GG 113 (75.8 %) 120 (75 %)
GA 36 (24.2 %) 38 (23.8 %) 1.007 0.597 - 1.699 0.980
AA 0 2 (1.2 %) 0.642 - - 0.999
GA + AA 36 (24.2 %) 40 (25 %) 0.895 0.956 0.569 - 1.605 0.865
MAF 0.12 0.13 1 0.09 0.738 1
APOE, rs7412, rs429358 0.995
No of pts (n) 154 160
*2/*2 1 (0.6 %) 0 - - 1.000
2.3 12 (7.8 %) 15 (9.4 %) 0.814 0.363 - 1.826 0.618
2.4 2 (1.3 %) 2 (1.2 %) 1.019 0.141 - 7.369 0.985
*2/*2; *2/*3; *2/*4 15 (9.7 %) 17 (10.6 %) 0.975 0.899 0.427 - 1.896 0.781
3/3 (wild) 106 (68.8 %) 108 (67.5 %) 0.952
3.4 31 (20.1 %) 32 (20 %) 0.987 0.563 - 1.732 0.964
4.4 2 (1.3 %) 3 (1.9 %) 0.680 0.111 - 4.152 0.676
3/4;4/4 33 (21.4 %) 35 (21.9 %) 0.960 0.556 - 1.658 0.885
MAF *2 0.05 0.05 1 0.08 0.343 0.383
MAF *4 0.11 0.12 1 0.14 0.831 1
GC, rs7041 0.722
No of pts (n) 154 160
TT 17 (11 %) 19 (11.9 %)
TG 83 (53.9 %) 79 (49.4 %) 1.176 0.570 - 2.424 0.661
GG 54 (35.1 %) 62 (38.8 %) 0.741 0.974 0.460 - 2.060 0.945
TG + GG 137 (89 %) 141 (88.1 %) 0.861 1.086 0.542 - 2.178 0.815
MAF 0.38 0.37 1 0.43 0.374 1
GC, rs4588 0.803
No of pts (n) 149 160
CC 73 (49 %) 82 (51.2 %)
CA 64 (43 %) 68 (42.5 %) 1.059 0.665 - 1.686 0.810
AA 12 (8.1 %) 10 (6.2 %) 0.821 1.350 0.551 - 3.311 0.512













Table 3 Distribution of polymorphism genotypes in groups with and without ISR, minor alele frequencies (MAF) and logistic regression analysis, separately for each parameter
with adjustment for diabetes mellitus (Continued)
MAF 0.29 0.28 1 0.31 1 1
VDR, rs2228570 0.913
No of pts (n) 149 160
TT 30 (20.1 %) 32 (20 %)
TC 70 (47 %) 79 (49.4 %) 0.945 0.552 - 1.544 0.760
CC 49 (32.9 %) 49 (30.6 %) 0.9 1.065 0.169 - 3.577 0.747
TC + CC 119 (79.9 %) 128 (80 %) 1 0.991 0.553 - 1.498 0.711
MAF 0.43 0.45 1 0.43 1 1
LRP1, rs1799986 0.913
No of pts (n) 149 160
CC 109 (73.2 %) 114 (71.2 %)
CT 37 (24.8 %) 42 (26.2 %) 0.923 0.552 - 1.544 0.760
TT 3 (2.0 %) 4 (2.5 %) 0.941 0.778 0.169 - 3.577 0.747
CT + TT 40 (26.8 %) 46 (28.8 %) 0.8 0.910 0.553 - 1.498 0.711
MAF 0.14 0.15 1 0.16 1 1
LDLR, rs2228671 0.716
No of pts (n) 149 160
CC 124 (83.2 %) 130 (81.2 %)
CT 22 (14.8 %) 28 (17.5 %) 0.824 0.447 - 1.516 0.533
TT 3 (2 %) 2 (1.2 %) 0.679 1.579 0.259 - 9.617 0.620
CT + TT 25 (16.9 %) 30 (18.8 %) 0.659 0.874 0.487 - 1.569 0.651
MAF 0.09 0.1 1 0.1 1 1
p = chi-square test
GP general population, CZ Czech













and reparative process. The acute vascular reaction is
characterized by early deposition of platelets and fibrin.
Activated platelets attach to circulating leukocytes
(neutrophils and monocytes) at the injured surface.
Over weeks, acute inflammatory cells are replaced by
chronic inflammatory cells (macrophages and giant
cells). In addition to this inflammatory response, plate-
let- and leukocyte-related growth factors drive further
VSMC proliferation and migration from the media to
the nascent neointima and subsequent extracellular
matrix formation.
Two weeks following bare-metal stent implantation, a
complete neointimal layer, composed of VSMCs and a
proteoglycan-rich extracellular matrix, can be observed
above stent struts. Excessive VSMC proliferation and
extracellular matrix formation lead to neointimal hyper-
plasia, which represents the major pathophysiologic
mechanism of ISR. Peak of BMS restenosis is observed
at 3–6 months and remains relatively stable beyond
1 year [13].
In our study, the ISR and the control groups of patients
did not differ significantly in the main demographic, clin-
ical, angiografic and biochemical parameters, with the ex-
ception of total and LDL cholesterol levels, that were
significantly higher in the control group. However, we do
not consider this difference important in the context of
the study results, as BCHE is not involved in cholesterol
metabolism and no differences were detected in LDLR
and LRP1 SNPs between the groups.
Oguri et al. reported that the rs1803274 polymorphism
of BCHE, rs529038 polymorphism of ROS1, and rs1050450
polymorphism of GPX1 were significantly associated (p <
0.05) with ISR and that the rs1800849 polymorphism of
UCP3 was associated with recurrent ISR (p = 0.0006) in
the Japanese population [3, 4].
Our results show that the rs1803274 (1699G>A,
p.Ala567Thr) polymorphism of BCHE was also signifi-
cantly associated with ISR in the Central European
population and that the A allele represents a risk factor
for this condition.
We analyzed this association only in the setting of a
dominant model, i.e. minor allele homozygotes plus het-
erozygotes (AA and GA) versus major allele homozy-
gotes (GG), as the confidence interval for rs1803274
homozygotes AA versus GG is too wide, probably due to
the low number of AA homozygotes.
A significant difference was also found for rs1803274
minor allele frequencies between the ISR and non ISR
groups. However, such a difference was not proved for
either the ISR or non ISR groups compared to general
Czech population. This may be due to a relatively small
sample size.
Butyrylcholinesterase (BCHE) is a secretion enzyme
produced by liver cells and released into the bloodstream.
In plasma, it contributes to cholinesterase activity, but its
endogenous substrate is not known. Cholinesterase
synthesis and its activity in plasma are decreased after
liver parenchyma damage or in the case of insufficient
protein intake in the diet. Previous studies have reported a
significant association between serum BCHE activity and
metabolic syndrome risk variables, such as high body
mass index, plasma concentrations of triglycerides and
HDL cholesterol, and blood pressure [14]. BCH E co-
participates in the hydrolysis of aspirin and thus could
affect its bioavailability and ability to inhibit platelet aggre-
gation [15]. The rs1803274 (the so-called K-variant) SNP
could be associated with type 2 diabetes mellitus; on the
other hand, results are conflicting on the association
between this SNP and early onset of coronary artery
disease [16, 17]. The underlying mechanism of the associ-
ation between the rs1803274 polymorphism of BCHE and
ISR remains to be elucidated.
Although the rs1050450 polymorphism of the GPX1
gene has also been associated with an increased risk of
ISR in Russian individuals [18] and in the Gender study
[19], we found no relationships between the polymor-
phisms of ROS1, GPX1, and UCP3 and ISR in the
Central European population.
Arachidonate 5-lipoxygenase-activating protein
(ALOX5AP) has an important role in the initial steps of
the biosynthesis of leukotrienes, which in turn have a var-
iety of proinflammatory effects [20]. Shah et al. found a
significant association between the occurrence of ISR and
rs17216473 in a North American population [5]. In con-
trast to their results, however, we could not confirm the
association between rs17216473 and the risk of ISR in a
Central European population.
In addition to the above genes, we focused on a
group of genes affecting metabolic processes including
APOE, VDR, GC, LRP1 and LDLR. The corresponding
proteins may be involved not only in atherosclerosis
but also in inflammation and may influence prolifera-
tion and migration of SMCs, key players in ISR devel-
opment [6–11].
Apolipoprotein E (APOE) plays an important role not
only in the metabolism of cholesterol and triglycerides
but also in inhibiting growth factor–induced SMC mi-
gration and proliferation and limiting neointimal hyper-
plasia after arterial injury [6, 7, 21]. APOE deficiency has
been associated with increased neointima formation
after vessel wall injury [22]. In an apoE-knockout mouse
model, the in-stent neointimal area was greater com-
pared with wild-type mice [22]. Although the level of
APOE could play a protective role against various forms
of vascular disease, including atherosclerosis and injury-
induced restenosis, we did not observe a significant
correlation between the APOE*2, *3, and *4 polymor-
phisms and the risk of ISR. Koch et al. made a similar
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observation, concluding that some APOE polymor-
phisms, i.e., APOE –219G>T, 113G>C, 334T>C
(APOE*4), and 472C>T (APOE*2) either alone or in
combination do not represent genetic markers of the
risk of ISR or stent thrombosis in German patients with
coronary artery disease [21].
Vitamin D is involved not only in bone metabolism
but also in modulating immune responses and cell
proliferation. The active form of vitamin D achieves its
biological effects by binding to the VDR, which is
expressed in most tissues and cells, including cardiac
myocytes, VSMCs and endothelial cells [8, 9]. In vivo
and in vitro studies have shown that down-regulation of
VDR in SMCs of post-interventional arteries could be
involved in the uncontrolled growth of SMCs, leading to
neointimal hyperplasia and restenosis [10]. We have
studied the rs2228570 polymorphism of the VDR gene
(known as a Fok I variant according to the restriction
enzyme used to detect it previously) and the rs7041 and
rs4588 polymorphisms of the GC gene encoding vita-
min D binding protein (DBP) and found that none of
these polymorphisms was associated with the risk of
ISR in this population. The findings regarding the
rs2228570 in VDR gene correspond to the results of the
study by Monraats et al. Although some substitutions
(the -1012A>G, −25C>A and 464G>T) of the VDR gene
increased the risk of clinical restenosis in their study,
such an association was not proved for rs2228570 [23].
The members of the low-density lipoprotein receptor
family (the LRs) such as low-density lipoprotein recep-
tor (LDLR), low-density lipoprotein receptor-related
protein-1 (LRP1), and others play a key role not only
in lipoprotein metabolism but also in the catabolism of
many membrane-associated proteins [11]. LRs can
influence the migration and proliferation of SMCs
through urokinase-type plasminogen activator receptor
(uPA) and the platelet-derived growth factor (PDGF)
receptor. Neither the rs1799986 polymorphism of LRP1
nor the rs2228671 polymorphism of LDLR were signifi-
cantly associated with the risk of ISR in our study.
Limitations
Several limitations of our study need to be mentioned.
This study could be limited by its observational nature
and a relatively small sample size. Nevertheless, we
believe that selection bias did not play a major role,
because both patient cohorts did not differ with respect
to main baseline parameters. As non-invasive MS-CT
coronarography was used in control group to confirm
the stent patency, it is not possible to avoid completely
potential false negatives findings. However, in previous
studies, MS-CT coronarography revealed sufficient ac-
curacy for ISR detection [24, 25].
Conclusion
Our results show that the rs1803274 polymorphism of
BCHE was significantly associated with ISR in our
Central European patients after PCI with bare-metal
stent implantation. The A allele of this polymorphism
represents a risk factor for this condition. The underlying
molecular mechanism of the association between this
polymorphism and ISR remains to be elucidated. No asso-
ciation was found with the other studied SNPs, including
rs529038 (ROS1), rs1050450 (GPX1), rs1800849 (UCP3),
rs17216473 (ALOX5AP), rs7412, rs429358 (APOE),
rs2228570 (VDR), rs7041, rs4588 (GC), rs1799986 (LRP1),
and rs2228671 (LDLR).
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